| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 05, 2024 |
Director, PRESIDENT AND CEO
Trans History: 29
|
Director, PRESIDENT AND CEO | Form 4 | Other acquisition or disposition | -- | -- | 502 |
| Sep 20, 2023 |
Chief Financial Officer
Trans History: 2
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Sep 18, 2023 |
Chief Financial Officer
Trans History: 2
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 106,000 | -- | 106,000 |
| Sep 18, 2023 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 317,842 |
| Sep 18, 2023 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 |
| Jun 14, 2023 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
| Jun 14, 2023 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 250,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.